John Overdeck’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-331,243
| Closed | -$1.63M | – | 5128 |
|
|
2021
Q3 | $1.63M | Sell |
331,243
-246,916
| -43% | -$1.2M | ﹤0.01% | 2175 |
|
|
2021
Q2 | $3.05M | Buy |
578,159
+150,701
| +35% | +$780K | 0.01% | 1540 |
|
|
2021
Q1 | $2.05M | Buy |
427,458
+252,924
| +145% | +$1.32M | 0.01% | 1692 |
|
|
2020
Q4 | $756K | Buy |
174,534
+35,475
| +26% | +$152K | ﹤0.01% | 2205 |
|
|
2020
Q3 | $573K | Buy |
+139,059
| New | +$538K | ﹤0.01% | 2142 |
|
|
2019
Q4 | – | Sell |
-58,231
| Closed | -$298K | – | 4104 |
|
|
2019
Q3 | $298K | Buy |
58,231
+30,511
| +110% | +$188K | ﹤0.01% | 2970 |
|
|
2019
Q2 | $172K | Sell |
27,720
-13,991
| -34% | -$80.5K | ﹤0.01% | 3122 |
|
|
2019
Q1 | $297K | Sell |
41,711
-36,478
| -47% | -$328K | ﹤0.01% | 2603 |
|
|
2018
Q4 | $668K | Buy |
+78,189
| New | +$1.02M | ﹤0.01% | 1909 |
|
|
2016
Q1 | – | Sell |
-19,876
| Closed | -$563K | – | 3230 |
|
|
2015
Q4 | $563K | Buy |
+19,876
| New | +$335K | ﹤0.01% | 1890 |
|
|
2015
Q3 | – | Sell |
-29,800
| Closed | -$781K | – | 2891 |
|
|
2015
Q2 | $781K | Buy |
+29,800
| New | +$580K | ﹤0.01% | 1827 |
|
John Overdeck's ADMS Position: Q4 2021 in Review
John Overdeck sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 331,243 shares — an estimated $1.63M sold.
John Overdeck first reported a position in ADMS in Q2 2015 and held it in 11 quarters. The position peaked at $3.05M in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- John Overdeck reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- John Overdeck sold 331,243 Adamas Pharmaceuticals shares in Q4 2021, an estimated $1.63M.
- John Overdeck first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 11 quarters.
- John Overdeck's Adamas Pharmaceuticals position peaked at $3.05M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Two Sigma Investments's 13F filing for Q4 2021, filed 14 Feb 2022.